Cargando…

Efficacy and safety of intracoronary epinephrine for the management of the no-reflow phenomenon following percutaneous coronary interventions: a systematic-review study

BACKGROUND: Currently, no pharmacological or device-based intervention has been fully proven to reverse the no-reflow phenomenon. OBJECTIVES: To assess the efficacy and safety of intracoronary (IC) epinephrine in the management of no-reflow phenomenon following percutaneous coronary intervention (PC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jafari Afshar, Elmira, Samimisedeh, Parham, Tayebi, Amirhossein, Shafiabadi Hassani, Neda, Rastad, Hadith, Yazdani, Shahrooz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071100/ https://www.ncbi.nlm.nih.gov/pubmed/36852839 http://dx.doi.org/10.1177/17539447231154654

Ejemplares similares

Clinical features and outcomes of Myasthenia Gravis associated with COVID-19 vaccines: A systematic review and pooled analysis
por: Tayebi, Amir Hossein, et al.
Publicado: (2023)

Intracoronary epinephrine versus adenosine in the management of refractory no-reflow phenomenon: a single-center retrospective cohort study
por: Darwish, Ahmed, et al.
Publicado: (2022)

Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective study
por: Aksu, Tolga, et al.
Publicado: (2015)

Comparison of Intracoronary Epinephrine and Adenosine for No-Reflow in Normotensive Patients With Acute Coronary Syndrome (COAR Trial)
por: Khan, Kamran Ahmed, et al.
Publicado: (2022)

COVID-19 Associated Fulminant Myocarditis in a Fully-Vaccinated Female: A Case Report with Clinical Follow-up
por: Samimisedeh, Parham, et al.
Publicado: (2023)

Intracoronary pressure gradient measurement in acute myocardial infarction patients with the no-reflow phenomenon during primary percutaneous coronary intervention
por: Gao, Ming-Dong, et al.
Publicado: (2020)

Meta-analysis of randomized controlled trials on the efficacy and safety of intracoronary administration of tirofiban for no-reflow phenomenon
por: Qin, Tao, et al.
Publicado: (2013)

Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction
por: Qi, Qi, et al.
Publicado: (2018)

Usefulness of Intracoronary Epinephrine in Severe Hypotension during Percutaneous Coronary Interventions
por: Choi, Jin Hee, et al.
Publicado: (2013)

No-Reflow Phoenomenon by Intracoronary Thrombus in Acute Myocardial Infarction
por: Lim, Sang Yup
Publicado: (2016)

Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction
por: ZHAO, YU-JUN, et al.
Publicado: (2013)

Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis
por: Niu, Xiaowei, et al.
Publicado: (2018)

Management of no Reflow during Percutaneous Transcoronary Angioplasty with Catheter-Directed Intracoronary Thrombolysis: A Retrospective Observational Study
por: Singh, Rakendra, et al.
Publicado: (2022)

No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction
por: Gupta, Sanjiv, et al.
Publicado: (2016)

The SALINE Technique for the Treatment of the No-Reflow Phenomenon during Percutaneous Coronary Intervention in STEMI
por: Grancini, Luca, et al.
Publicado: (2023)

No-Reflow Phenomenon and Endothelial Glycocalyx of Microcirculation
por: Maksimenko, Alexander V., et al.
Publicado: (2012)

“No-Reflow” Phenomenon: A Contemporary Review
por: Annibali, Gianmarco, et al.
Publicado: (2022)

Congenital Bladder and Urethral Agenesis: Two Case Reports and Management
por: Delshad, Salahaddin, et al.
Publicado: (2020)

Correlates of the “No-Reflow” or “Slow-Flow” Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention
por: Alidoosti, Mohammad, et al.
Publicado: (2018)

Evaluation of the Clinical and Procedural Predictive Factors of no-Reflow Phenomenon Following Primary Percutaneous Coronary Intervention
por: Abdi, Seifollah, et al.
Publicado: (2015)

hsCRP and ET-1 expressions in patients with no-reflow phenomenon after Percutaneous Coronary Intervention
por: Liu, Min, et al.
Publicado: (2017)

Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts
por: Hashemi-Jazi, Mohammad, et al.
Publicado: (2017)

Comparison of no-reflow phenomenon after percutaneous coronary intervention for acute myocardial infarction between smokers and nonsmokers
por: Shemirani, Hassan, et al.
Publicado: (2014)

No-reflow phenomenon during percutaneous coronary intervention in a patient with polycythemia vera: A case report
por: Oktaviono, Yudi Her, et al.
Publicado: (2020)

Non-pharmaco, non-invasive management of coronary no-reflow phenomenon
por: Sinha, Santosh Kumar, et al.
Publicado: (2020)

The No-reflow Phenomenon: Is it Predictable by Demographic factors and Routine Laboratory Data?
por: Namazi, Mohammadhasan, et al.
Publicado: (2021)

Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction
por: Yang, Li, et al.
Publicado: (2020)

In-Hospital Peak Glycemia in Predicting No-Reflow Phenomenon in Diabetic Patients with STEMI Treated with Primary Percutaneous Coronary Intervention
por: Liu, Fang, et al.
Publicado: (2021)

CHA2DS2-VASc Score Predict No-Reflow Phenomenon in Primary Percutaneous Coronary Intervention in Primary Percutaneous Coronary Intervention
por: Mirbolouk, Fardin, et al.
Publicado: (2018)

Intracoronary injection of nitroglycerine can prevent unnecessary percutaneous coronary intervention
por: Nasiri-Partovi, Amirhossein, et al.
Publicado: (2022)

Effects of no-reflow phenomenon on ventricular systolic synchrony in patients with acute anterior myocardial infarction after percutaneous coronary intervention
por: Wang, Le, et al.
Publicado: (2016)

The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis
por: Fajar, Jonny Karunia, et al.
Publicado: (2018)

Serum cystatin C levels relate to no-reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction
por: Cheng, Chao, et al.
Publicado: (2019)

Platelet/lymphocyte ratio for prediction of no-reflow phenomenon in ST-elevation myocardial infarction managed with primary percutaneous coronary intervention
por: Badran, Hala Mahfouz, et al.
Publicado: (2020)

Impact of Stress Hyperglycemia on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Khalfallah, Mohamed, et al.
Publicado: (2022)

The Impact of Kidney Function on the Slow-Flow/No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention: Registry Analysis
por: Savic, Lidija, et al.
Publicado: (2022)

Intravascular Ultrasound Observation of the Mechanism of No-Reflow Phenomenon in Acute Myocardial Infarction
por: Li, Junxia, et al.
Publicado: (2015)

A Narrative Review of the Classical and Modern Diagnostic Methods of the No-Reflow Phenomenon
por: Pantea-Roșan, Larisa Renata, et al.
Publicado: (2022)

The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Somuncu, Mustafa Umut, et al.
Publicado: (2019)

Impact of the Total Ischemia Time on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Khalfallah, Mohamed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ag3fusgk8jdrsa3vmjsajajagb